secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010098
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q1 2025: cash burn $5.0M; $3.9M cash; needs capital beyond Q2 2025; Decoy20 combo trial started
--------------------------------------------------------------------------------

- Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.
- Net loss per share $0.32 in Q1 2025 vs $0.45 in Q1 2024; R&D expenses $2.8M (up from $1.6M) due to Phase 1 trial costs.
- Initiated Phase 1b/2 combination arm of Decoy20 with BeOne's PD-1 inhibitor Tislelizumab; weekly dosing arm concluded after 32 patients.
- Patents granted in China, Japan, Israel for Decoy platform; cost-reduction plan implemented to focus on combination study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000164117225010098/0001641172-25-010098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000164117225010098/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer